Generic Products

Medicure offers a growing product portfolio of acute care injectable products that improve patients' lives. Medicure announced on August 13, 2018, that the United States Food and Drug Administration had approved its Abbreviated New Drug Application ("ANDA") for Sodium Nitroprusside Injection 50 mg/2 mL (25 mg/mL) single dose vial ("SNP"), a generic intravenous cardiovascular drug product. The filing of the ANDA was previously announced by Medicure on December 13, 2016.

Medicure is developing 2 additional generic products focusing on the acute care cardiovascular injectables for the U.S. hospital market. We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients, healthcare providers, and shareholders. Our commitment to service, partnership and integrity are what sets us apart.